Zoster Vaccination

The presentation focuses on zoster vaccination, particularly highlighting the importance of prevention of shingles (herpes zoster) through vaccination strategies. It references the historical use of the live attenuated varicella vaccine (Varivax) since 1995 and discusses the need for immunization against chicken pox as a preventive measure against zoster in older populations. The session details the evolution of zoster vaccines, emphasizing the efficacy of Zostavax and the newer Shingrix vaccine, which offers approximately 97% reduction in the incidence of zoster and postherpetic neuralgia in populations over 50. The speaker underscores the advantages of Shingrix, stating it does not contain live virus, which eliminates the risk of contracting chicken pox or shingles from the vaccine itself. Recommendations include vaccination for all adults over 50, irrespective of prior zoster vaccination, and for immunocompromised individuals over 18 years old. Practical considerations about vaccination timing and common side effects are addressed, with an emphasis on the necessity of preventing reactivation of the varicella-zoster virus through effective immunization. The speaker reassures that the risk of adverse reactions is minimal and discusses the implications for those who may not remember having chicken pox, stressing that many adults are seropositive regardless of memory of illness. The lecture concludes on a hopeful note about future vaccination strategies against herpes simplex virus.